Prognostic Value of SPARCL1 in Patients with Colorectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 14

PMID 29434834

Citations 5

Authors

Wei Han

Fang Cao

Wei Ding

Xiao-Jiao Gao

Fang Chen

Yong-Wei Hu

Hou-Zhong Ding

Affiliations

Soon will be listed here.

Abstract

Secreted protein acidic and rich in cysteine-like 1 (SPARCL1), a member of extracelluar matrix glycoprotein, has been reported to be associated with various tumor types. The present study aimed to evaluate the prognostic value of SPARCL1 in patients with colorectal cancer. Tissue microarray blocks were constructed based on 79 patients who underwent radical surgery at the Kunshan First People's Hospital between 2008 and 2010. Thirty pairs of fresh-frozen tissues were also obtained for total protein extraction. The expression of SPARCL1 protein was analyzed using immunohistochemistry and western blotting analyses, and the association between overexpressed SPARCL1 and clinicopathological factors was evaluated. Survival analysis with Kaplan Meier curves and Cox regression analysis was used to analyze the prognostic value of SPARCL1. According to western blot analyses, SPARCL1 protein expression in colorectal tumors was significantly lower compared with corresponding normal tissues. The expression of SPARCL1 was markedly decreased from differentiation I to III, and the negative rate of SPARCL1 was higher at Duke's stage C compared with B. Though without any difference between 'positive' and 'negative' in overall survival, significantly higher survival in patients with positive SPARCL1 expression at Duke's stage B was detected in the present study. These results indicated that SPARCL1 may be a potential tumor suppressor gene and associated with good prognosis.

Citing Articles

Propensity score matching as an effective strategy for biomarker cohort design and omics data analysis.

Maekawa M, Tanaka A, Ogawa M, Roehrl M PLoS One. 2024; 19(5):e0302109.

PMID: 38696425 PMC: 11065211. DOI: 10.1371/journal.pone.0302109.

Sparcl1 and Atherosclerosis.

Cheng X, Chen X, Zhang M, Wan Y, Ge S, Cheng X J Inflamm Res. 2023; 16:2121-2127.

PMID: 37220502 PMC: 10200116. DOI: 10.2147/JIR.S406907.

SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.

Zhang H, Wu J, Liu Z, Gao J, Li S Biomed Res Int. 2022; 2022:1398268.

PMID: 35111844 PMC: 8803425. DOI: 10.1155/2022/1398268.

Identification of Hub Genes and Construction of a Transcriptional Regulatory Network Associated With Tumor Recurrence in Colorectal Cancer by Weighted Gene Co-expression Network Analysis.

Liu S, Zeng F, Fan G, Dong Q Front Genet. 2021; 12:649752.

PMID: 33897765 PMC: 8058478. DOI: 10.3389/fgene.2021.649752.

Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.

Klingler A, Regensburger D, Tenkerian C, Britzen-Laurent N, Hartmann A, Sturzl M PLoS One. 2020; 15(5):e0233422.

PMID: 32437418 PMC: 7241726. DOI: 10.1371/journal.pone.0233422.

References

Esposito I, Kayed H, Keleg S, Giese T, Sage E, Schirmacher P . Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007; 9(1):8-17. PMC: 1803032. DOI: 10.1593/neo.06646. View

Isler S, Ludwig C, Chiquet-Ehrismann R, Schenk S . Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol. 2004; 25(4):1073-9. View

Han W, Cao F, Chen M, Lu R, Wang H, Yu M . Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(1):e0145803. PMC: 4701416. DOI: 10.1371/journal.pone.0145803. View

Jakharia A, Borkakoty B, Singh S . Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma. J Gastrointest Oncol. 2016; 7(2):278-83. PMC: 4783736. DOI: 10.3978/j.issn.2078-6891.2015.064. View

Kotti A, Holmqvist A, Albertsson M, Sun X . SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients. Int J Radiat Oncol Biol Phys. 2014; 88(5):1196-202. DOI: 10.1016/j.ijrobp.2013.12.041. View

Wang Z, Hao B, Yang Y, Wang R, Li Y, Wu Q . Prognostic role of SPARC expression in gastric cancer: a meta-analysis. Arch Med Sci. 2014; 10(5):863-9. PMC: 4223132. DOI: 10.5114/aoms.2014.46207. View

Bendik I, Schraml P, Ludwig C . Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res. 1998; 58(4):626-9. View

Li P, Qian J, Yu G, Chen Y, Liu K, Li J . Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol. 2011; 105(1):31-7. DOI: 10.1002/jso.22025. View

Claeskens A, Ongenae N, Neefs J, Cheyns P, Kaijen P, Cools M . Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000; 82(6):1123-30. PMC: 2363342. DOI: 10.1054/bjoc.1999.1051. View

10.

Yu S, Yu J, Ge W, Hu H, Yuan Y, Zheng S . SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol. 2011; 17(15):2028-36. PMC: 3082758. DOI: 10.3748/wjg.v17.i15.2028. View

11.

Isler S, Schenk S, Bendik I, Schraml P, Novotna H, Moch H . Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol. 2001; 18(3):521-6. DOI: 10.3892/ijo.18.3.521. View

12.

Girard J, Springer T . Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995; 2(1):113-23. DOI: 10.1016/1074-7613(95)90083-7. View

13.

Cao F, Wang K, Zhu R, Hu Y, Fang W, Ding H . Clinicopathological significance of reduced SPARCL1 expression in human breast cancer. Asian Pac J Cancer Prev. 2013; 14(1):195-200. DOI: 10.7314/apjcp.2013.14.1.195. View

14.

Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, Buecher B . Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer. 1999; 81(6):854-8. DOI: 10.1002/(sici)1097-0215(19990611)81:6<854::aid-ijc3>3.0.co;2-1. View

15.

Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P . Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 2012; 18(19):5438-48. DOI: 10.1158/1078-0432.CCR-12-0124. View

16.

Lau C, Poon R, Cheung S, Yu W, Fan S . SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol. 2006; 210(4):459-68. DOI: 10.1002/path.2068. View

17.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann B, Strand D . SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol. 2013; 7(6):1019-30. PMC: 3838491. DOI: 10.1016/j.molonc.2013.07.008. View

18.

Ng L, Poon R, Pang R . Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci. 2013; 70(19):3631-56. PMC: 11113832. DOI: 10.1007/s00018-013-1266-8. View

19.

Liu Q, Gao X, Chang W, Wang H, Wang H, Cao G . Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis. Eur Rev Med Pharmacol Sci. 2015; 19(10):1803-11. View

20.

Bradshaw A . Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012; 44(3):480-8. PMC: 3312742. DOI: 10.1016/j.biocel.2011.12.021. View